Cubist, XTL antibody deal

CBST licensed from XTL Biopharmaceuticals (LSE:XTL) worldwide development and commercialization rights to XTL's HepeX-B, a monoclonal antibody in Phase IIb testing to prevent re-infection of HBV in li...